About vasopharm

Corporate Profile


We develop novel therapeutics for acute inflammatory central nervous system conditions by targeting nitric oxide signalling pathways.

Business Model

vasopharm focuses on drug development in central nervous system (CNS) niche indications with a high unmet medical need. We have taken a small molecule (VAS203) targeting pathological nitric oxide (NO) production and signalling from discovery to a pivotal clinical trial.


vasopharm was founded in July 1998 as a spin-off from the University of Wuerzburg Medical School by Harald Schmidt, MD, PhD, Professor of Pharmacology and Toxicology, and Ulrich Walter, MD, Professor of Clinical Biochemistry and Pathobiochemistry. In December 2015, vasopharm closed a Series G financing round amounting to EUR 22 million followed by enrolling the first patient in to the NOSTRA III trial – a phase III clinical trial assessing efficacy and safety of VAS203 for the treatment of moderately to severely injured closed head traumatic brain injury patients in September 2016. The NOSTRA III trial was successfully completed in June 2020 with data lock in July 2020.

2021, Mar. Successful completion of validation of drug substance manufacturing process
2021, Jan. Prof Stover, MD joins vasopharm as new Chief Medical Officer
2020, Jun. Last Patient Last Visit of NOSTRA III trial
2019, Dec. Last patient enrolled into NOSTRA III trial
2019, Jan. Efficacy Interim Analysis of NOSTRA III trial by DMC
2018, Jul. 3rd Safety Interim Analysis of NOSTRA III trial by DMC
2017, Dec. 2nd Safety Interim Analysis of NOSTRA III trial by DMC
2017, Jul. 1st Safety Interim Analysis of NOSTRA III trial by DMC
2017, Feb Successful completion of clinical phase Ic trial in healthy volunteers
2016, Nov Appointment of new Chief Medical Officer
2016, Sep First Patient In – NOSTRA III trial; a European placebo-controlled, randomised, double-blind, multi-centre study in patients with moderate and severe traumatic brain injury
2015, Dec. Series G Financing Round (EUR 22.0 m)
2013, Jun Series F Financing Round (EUR 5.0 m)
2012, Apr Completion of patient treatment in phase IIa NOSTRA trial with VAS203
2009, Nov First Patient In phase IIa explorative European multicentre trial
2009, May Series D Financing round (EUR 4.5 m)
2008, Jun Successful completion of clinical phase Ib study with multiple application of vasopharm’s compound VAS203
2007, Jul Successful completion of first-in-man study with vasopharm's compound VAS203
2006, Dec First human study with vasopharm's trauma compound VAS203
2006, Sep European Commission Grants Orphan Medicinal Product Designation for vasopharm's drug candidate VAS203
2006, Jan Series B Financing round with EMBL Ventures as Lead Investor (EUR 9.7 m)
2004, Nov New investor Entrepreneurs Fund B.V., Amsterdam
2004, Oct Patent license agreement with Pfizer Inc., USA
2004, Feb Grant of the Bavarian Research Foundation for Nox inhibitors
2003, Mar Start of GMP production of VAS203
2002, Oct License Agreement with BioCytex, Marseille (Cytometric VASP Assay for Clopidogrel® monitoring)
2001, Aug Series A Financing round with 3i Group Investments LP as Lead Investor (EUR 6.5 m)
1998, Jul Foundation of vasopharm; Business Model: Fee for Service for the pharmaceutical industry until end of 2000